EDUCATION

Internship

  • Boston Children's Hospital , 1992 , Boston , MA

Medical School

  • Harvard Medical School , 1991 , Boston , MA

Residency

Pediatrics
  • Boston Combined Residency Program (BCRP) , 1994 , Boston , MA

Fellowship

Pediatric Hematology -Oncology
  • Boston Children's Hospital/Dana-Farber Cancer Institute , 1997 , Boston , MA

PROFESSIONAL HISTORY

Dr. Silverman received his MD from Harvard Medical School in 1991 and training in pediatrics at Boston Children's Hospital in 1994. He subsequently completed a fellowship in pediatric hematology-oncology at Boston Children's Hospital and Dana-Farber Cancer Institute. In 1997, he became an attending physician in pediatric hematology-oncology at Dana-Farber/Boston Children's, and today, he is Vice Chair for Clinical Affairs, Department of Pediatric Oncology, at Dana-Farber Cancer Institute and Associate Chief, Pediatric Oncology, at Boston Children's Hospital. Dr. Silverman also leads the DFCI/ALL Consortium, which conducts multi-institutional clinical trials for children and adolescents with newly diagnosed acute lymphoblastic leukemia.

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-risk Leukemias: A Report from the LEAP Consortium. Cancer Discov. 2021 Feb 09. View abstract
  2. Genetic ancestry and skeletal toxicities among childhood acute lymphoblastic leukemia patients in the DFCI 05-001 cohort. Blood Adv. 2021 Jan 26; 5(2):451-458. View abstract
  3. Corrigendum. Pediatr Blood Cancer. 2021 Mar; 68(3):e28885. View abstract
  4. Single cell RNA-seq reveals developmental plasticity with coexisting oncogenic and immune evasion programs in ETP-ALL. Blood. 2020 Nov 23. View abstract
  5. Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001. Pediatr Blood Cancer. 2021 Jan; 68(1):e28719. View abstract
  6. Fatal capillary leak syndrome in a child with acute lymphoblastic leukemia treated with moxetumomab pasudotox for pre-transplant minimal residual disease reduction. Pediatr Blood Cancer. 2021 Jan; 68(1):e28574. View abstract
  7. Increasing completion of asparaginase treatment in childhood acute lymphoblastic leukaemia (ALL): summary of an expert panel discussion. ESMO Open. 2020 09; 5(5):e000977. View abstract
  8. How we approach Philadelphia chromosome-positive acute lymphoblastic leukemia in children and young adults. Pediatr Blood Cancer. 2020 10; 67(10):e28543. View abstract
  9. Reduced Morbidity and Mortality in Survivors of Childhood Acute Lymphoblastic Leukemia: A Report From the Childhood Cancer Survivor Study. J Clin Oncol. 2020 10 10; 38(29):3418-3429. View abstract
  10. HLA alleles associated with asparaginase hypersensitivity in childhood ALL: a report from the DFCI Consortium. Pharmacogenomics. 2020 06; 21(8):541-547. View abstract
  11. Protective Effects of Dietary Intake of Antioxidants and Treatment-Related Toxicity in Childhood Leukemia: A Report From the DALLT Cohort. J Clin Oncol. 2020 07 01; 38(19):2151-2159. View abstract
  12. Targeting EZH2 for the treatment of hepatosplenic T-cell lymphoma. Blood Adv. 2020 04 14; 4(7):1265-1269. View abstract
  13. Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 01; 18(1):81-112. View abstract
  14. Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL. Blood. 2019 12 26; 134(26):2361-2368. View abstract
  15. Fanconi-BRCA pathway mutations in childhood T-cell acute lymphoblastic leukemia. PLoS One. 2019; 14(11):e0221288. View abstract
  16. Genes identified through genome-wide association studies of osteonecrosis in childhood acute lymphoblastic leukemia patients. Pharmacogenomics. 2019 11; 20(17):1189-1197. View abstract
  17. Impact of DARC, GSDMA and CXCL2 polymorphisms on induction toxicity in children with acute lymphoblastic leukemia: A complementary study. Leuk Res. 2019 11; 86:106228. View abstract
  18. Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study. J Clin Oncol. 2019 09 01; 37(25):2246-2256. View abstract
  19. Divide and conquer: Evaluation of a redesign of a pediatric teaching service. Pediatr Blood Cancer. 2019 07; 66(7):e27738. View abstract
  20. Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Retrospective Multinational Study. J Clin Oncol. 2019 04 01; 37(10):770-779. View abstract
  21. Fluctuations in dietary intake during treatment for childhood leukemia: A report from the DALLT cohort. Clin Nutr. 2019 12; 38(6):2866-2874. View abstract
  22. A single institutional review of pediatric Bacillus spp. bloodstream infections demonstrates increased incidence among children with cancer. Pediatr Blood Cancer. 2019 04; 66(4):e27568. View abstract
  23. Trypsin-encoding PRSS1-PRSS2 variations influence the risk of asparaginase-associated pancreatitis in children with acute lymphoblastic leukemia: a Ponte di Legno toxicity working group report. Haematologica. 2019 03; 104(3):556-563. View abstract
  24. PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia. J Exp Med. 2018 12 03; 215(12):3094-3114. View abstract
  25. Health Status and Health-related Quality of Life Measurement in Pediatric Cancer Clinical Trials: An Examination of the DFCI 00-01 Acute Lymphoblastic Leukemia Protocol. J Pediatr Hematol Oncol. 2018 11; 40(8):580-587. View abstract
  26. Genomic and clinical characterization of B/T mixed phenotype acute leukemia reveals recurrent features and T-ALL like mutations. Am J Hematol. 2018 11; 93(11):1358-1367. View abstract
  27. Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001. Blood Adv. 2018 06 26; 2(12):1449-1458. View abstract
  28. Outcome of children and adolescents with Down syndrome treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium protocols 00-001 and 05-001. Pediatr Blood Cancer. 2018 10; 65(10):e27256. View abstract
  29. Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622. J Clin Oncol. 2018 08 01; 36(22):2306-2314. View abstract
  30. Reply to comment on: Effectiveness of antibacterial prophylaxis during induction chemotherapy in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2018 08; 65(8):e27082. View abstract
  31. Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2018 07; 65(7):e27062. View abstract
  32. Hedgehog pathway mutations drive oncogenic transformation in high-risk T-cell acute lymphoblastic leukemia. Leukemia. 2018 10; 32(10):2126-2137. View abstract
  33. Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia. Blood Adv. 2018 03 13; 2(5):529-533. View abstract
  34. Role of CD81 and CD58 in minimal residual disease detection in pediatric B lymphoblastic leukemia. Int J Lab Hematol. 2018 Jun; 40(3):343-351. View abstract
  35. Effectiveness of antibacterial prophylaxis during induction chemotherapy in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2018 05; 65(5):e26952. View abstract
  36. Influence of BCL2L11 polymorphism on osteonecrosis during treatment of childhood acute lymphoblastic leukemia. Pharmacogenomics J. 2019 02; 19(1):33-41. View abstract
  37. Incorporation of nonchemotherapeutic agents in pediatric acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2017 12 08; 2017(1):259-264. View abstract
  38. Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol. Leukemia. 2017 12; 31(12):2854. View abstract
  39. An investigation of toxicities and survival in Hispanic children and adolescents with ALL: Results from the Dana-Farber Cancer Institute ALL Consortium protocol 05-001. Pediatr Blood Cancer. 2018 03; 65(3). View abstract
  40. TOX Regulates Growth, DNA Repair, and Genomic Instability in T-cell Acute Lymphoblastic Leukemia. Cancer Discov. 2017 11; 7(11):1336-1353. View abstract
  41. Phase I Study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia. Blood. 2017 Aug 09. View abstract
  42. Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia. Blood. 2017 10 05; 130(14):1620-1627. View abstract
  43. Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group study. Lancet Oncol. 2017 09; 18(9):1238-1248. View abstract
  44. Whole-exome sequencing identified genetic risk factors for asparaginase-related complications in childhood ALL patients. Oncotarget. 2017 Jul 04; 8(27):43752-43767. View abstract
  45. Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable Leukemia. Cell Stem Cell. 2017 03 02; 20(3):315-328.e7. View abstract
  46. Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia. Pharmacogenomics J. 2017 01; 17(1):107. View abstract
  47. A thymidylate synthase polymorphism is associated with increased risk for bone toxicity among children treated for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2017 Jul; 64(7). View abstract
  48. Synchronous occurrence of acute lymphoblastic leukemia and wilms tumor in two patients: underlying etiology and combined treatment plan. Pediatr Blood Cancer. 2017 05; 64(5). View abstract
  49. Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia. Clin Cancer Res. 2017 Feb 15; 23(4):1012-1024. View abstract
  50. Feasibility of baseline neurocognitive assessment using Cogstate during the first month of therapy for childhood leukemia. Support Care Cancer. 2017 02; 25(2):449-457. View abstract
  51. Treatment of Childhood Acute Lymphoblastic Leukemia: Prognostic Factors and Clinical Advances. Curr Hematol Malig Rep. 2016 10; 11(5):385-94. View abstract
  52. How Variable Is Our Delivery of Information? Approaches to Patient Education About Oral Chemotherapy in the Pediatric Oncology Clinic. J Pediatr Health Care. 2017 Jan - Feb; 31(1):e1-e6. View abstract
  53. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 07 11; 30(1):183. View abstract
  54. Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus. Lancet Oncol. 2016 06; 17(6):e231-e239. View abstract
  55. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 04 11; 29(4):574-586. View abstract
  56. Dietary intake and childhood leukemia: The Diet and Acute Lymphoblastic Leukemia Treatment (DALLT) cohort study. Nutrition. 2016 Oct; 32(10):1103-1109.e1. View abstract
  57. Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation. Haematologica. 2016 Mar; 101(3):279-85. View abstract
  58. A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. Clin Cancer Res. 2016 Aug 15; 22(16):4014-22. View abstract
  59. Impact of Socioeconomic Status on Timing of Relapse and Overall Survival for Children Treated on Dana-Farber Cancer Institute ALL Consortium Protocols (2000-2010). Pediatr Blood Cancer. 2016 Jun; 63(6):1012-8. View abstract
  60. Impaired mitochondrial function is abrogated by dexrazoxane in doxorubicin-treated childhood acute lymphoblastic leukemia survivors. Cancer. 2016 Mar 15; 122(6):946-53. View abstract
  61. Influence of Cranial Radiotherapy on Outcome in Children With Acute Lymphoblastic Leukemia Treated With Contemporary Therapy. J Clin Oncol. 2016 Mar 20; 34(9):919-26. View abstract
  62. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. Lancet Oncol. 2015 Dec; 16(16):1677-90. View abstract
  63. Bacillus cereus Cerebral Abscess During Induction Chemotherapy for Childhood Acute Leukemia. J Pediatr Hematol Oncol. 2015 Oct; 37(7):568-9. View abstract
  64. Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia. Pediatr Blood Cancer. 2016 Feb; 63(2):228-33. View abstract
  65. Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol. Leukemia. 2016 05; 30(5):1184-7. View abstract
  66. Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia. Pharmacogenomics J. 2016 11; 16(6):530-535. View abstract
  67. Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. J Clin Oncol. 2015 Sep 20; 33(27):2938-48. View abstract
  68. Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. Cancer Cell. 2015 Jul 13; 28(1):29-41. View abstract
  69. Cytogenetic Variation of B-Lymphoblastic Leukemia With Intrachromosomal Amplification of Chromosome 21 (iAMP21): A Multi-Institutional Series Review. Am J Clin Pathol. 2015 Jul; 144(1):103-12. View abstract
  70. Epigenetic and molecular signatures of cord blood CD34(+) cells treated with histone deacetylase inhibitors. Vox Sang. 2016 Jan; 110(1):79-89. View abstract
  71. Polymorphisms in Genes Related to Oxidative Stress Are Associated With Inferior Cognitive Function After Therapy for Childhood Acute Lymphoblastic Leukemia. J Clin Oncol. 2015 Jul 01; 33(19):2205-11. View abstract
  72. Balancing cure and long-term risks in acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2014 Dec 05; 2014(1):190-7. View abstract
  73. CNS prophylaxis in pediatric acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2014 Dec 05; 2014(1):198-201. View abstract
  74. Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science. 2014 Dec 12; 346(6215):1373-7. View abstract
  75. Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2015 Mar; 29(3):526-34. View abstract
  76. Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. Cancer Discov. 2014 Sep; 4(9):1074-87. View abstract
  77. Polymorphisms of asparaginase pathway and asparaginase-related complications in children with acute lymphoblastic leukemia. Clin Cancer Res. 2015 Jan 15; 21(2):329-34. View abstract
  78. Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia. Pharmacogenomics. 2014 Jun; 15(8):1105-16. View abstract
  79. Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation. Nat Genet. 2014 Jun; 46(6):618-23. View abstract
  80. Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia. Nat Commun. 2014 Mar 24; 5:3469. View abstract
  81. Repression of BIM mediates survival signaling by MYC and AKT in high-risk T-cell acute lymphoblastic leukemia. Leukemia. 2014 Sep; 28(9):1819-27. View abstract
  82. Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial. Pediatr Blood Cancer. 2014 Jul; 61(7):1232-8. View abstract
  83. c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells. Blood. 2014 Feb 13; 123(7):1040-50. View abstract
  84. Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group. Blood. 2014 Jan 02; 123(1):70-7. View abstract
  85. Challenges of phase III trial design for novel treatments in diseases with no standard treatment: the AZA-001 myelodysplasia study model. Leuk Res. 2014 Feb; 38(2):258-62. View abstract
  86. Impact of promoter polymorphisms in key regulators of the intrinsic apoptosis pathway on the outcome of childhood acute lymphoblastic leukemia. Haematologica. 2014 Feb; 99(2):314-21. View abstract
  87. Bim polymorphisms: influence on function and response to treatment in children with acute lymphoblastic leukemia. Clin Cancer Res. 2013 Sep 15; 19(18):5240-9. View abstract
  88. Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia. Cancer. 2013 Oct 01; 119(19):3555-62. View abstract
  89. Neuropsychological outcomes of a randomized trial of prednisone versus dexamethasone in acute lymphoblastic leukemia: findings from Dana-Farber Cancer Institute All Consortium Protocol 00-01. Pediatr Blood Cancer. 2013 Nov; 60(11):1785-91. View abstract
  90. Phase 1 study of intravenous rigosertib (ON 01910.Na), a novel benzyl styryl sulfone structure producing G2/M arrest and apoptosis, in adult patients with advanced cancer. Am J Cancer Res. 2013; 3(3):323-38. View abstract
  91. Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemia. J Clin Oncol. 2013 Jul 01; 31(19):2469-76. View abstract
  92. Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. J Clin Oncol. 2013 Mar 20; 31(9):1202-10. View abstract
  93. Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes. Pediatrics. 2012 Dec; 130(6):1003-11. View abstract
  94. Hematopoietic stem cell transplantation in unique pediatric populations: adolescents, infants, and children with down syndrome. Biol Blood Marrow Transplant. 2013 Jan; 19(1 Suppl):S52-7. View abstract
  95. The thirteenth international childhood acute lymphoblastic leukemia workshop report: La Jolla, CA, USA, December 7-9, 2011. Pediatr Blood Cancer. 2013 Feb; 60(2):344-8. View abstract
  96. Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations. Blood. 2012 Sep 06; 120(10):2076-86. View abstract
  97. Asparaginase-associated myelosuppression and effects on dosing of other chemotherapeutic agents in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2012 Nov; 59(5):925-7. View abstract
  98. Outcomes after induction failure in childhood acute lymphoblastic leukemia. N Engl J Med. 2012 Apr 12; 366(15):1371-81. View abstract
  99. Sequencing histone-modifying enzymes identifies UTX mutations in acute lymphoblastic leukemia. Leukemia. 2012 Aug; 26(8):1881-3. View abstract
  100. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol. 2012 Apr 01; 30(10):1042-9. View abstract
  101. Health-related quality of life among children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2012 Oct; 59(4):717-24. View abstract
  102. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science. 2011 Nov 25; 334(6059):1129-33. View abstract
  103. ATF5 polymorphisms influence ATF function and response to treatment in children with childhood acute lymphoblastic leukemia. Blood. 2011 Nov 24; 118(22):5883-90. View abstract
  104. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. Blood. 2011 Dec 01; 118(23):6043-9. View abstract
  105. The BCL11B tumor suppressor is mutated across the major molecular subtypes of T-cell acute lymphoblastic leukemia. Blood. 2011 Oct 13; 118(15):4169-73. View abstract
  106. Childhood T-all: it's time to move on. Blood. 2011 Jul 28; 118(4):828-9. View abstract
  107. Neuropsychological outcomes of standard risk and high risk patients treated for acute lymphoblastic leukemia on Dana-Farber ALL consortium protocol 95-01 at 5 years post-diagnosis. Pediatr Blood Cancer. 2012 May; 58(5):758-65. View abstract
  108. Impact of HFE mutations on cardiac status in survivors of childhood high-risk ALL: Dana-Farber Cancer Institute Childhood ALL 05-159. J Clin Oncol. 2011 May 20; 29(15_suppl):9508. View abstract
  109. L-asparaginase (L-ASP)-related toxicities with Erwinia L-ASP in a large compassionate-use protocol. J Clin Oncol. 2011 May 20; 29(15_suppl):9534. View abstract
  110. Changes in cardiovascular signaling proteins during doxorubicin treatment in children with high-risk ALL. J Clin Oncol. 2011 May 20; 29(15_suppl):9551. View abstract
  111. Neurobehavioral side effects of corticosteroids during active treatment for acute lymphoblastic leukemia in children are age-dependent: report from Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. Pediatr Blood Cancer. 2011 Sep; 57(3):492-8. View abstract
  112. The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium. Eur J Cancer. 2011 Jun; 47(9):1373-9. View abstract
  113. Therapeutic modalities for patients with lower-risk myelodysplastic syndromes: current options and future directions. Curr Hematol Malig Rep. 2011 Mar; 6(1):5-12. View abstract
  114. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol. 2011 Feb; 152(4):452-9. View abstract
  115. Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol. 2010 Nov 01; 28(31):4755-61. View abstract
  116. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol. 2010 Oct; 11(10):950-61. View abstract
  117. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer. 2011 Jan 15; 117(2):238-49. View abstract
  118. Jumping translocations of the long arms of chromosome 1 in myeloid malignancies is associated with a high risk of transformation to acute myeloid leukaemia. Br J Haematol. 2010 Nov; 151(3):288-91. View abstract
  119. Absence of biallelic TCRgamma deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemia. J Clin Oncol. 2010 Aug 20; 28(24):3816-23. View abstract
  120. Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conference. Pediatr Blood Cancer. 2010 Jul 01; 54(7):872-8. View abstract
  121. Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study. Blood. 2010 Oct 14; 116(15):2644-50. View abstract
  122. Inactivation of LEF1 in T-cell acute lymphoblastic leukemia. Blood. 2010 Apr 08; 115(14):2845-51. View abstract
  123. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2010 Feb; 54(2):199-205. View abstract
  124. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010 Feb 01; 28(4):562-9. View abstract
  125. Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000). Leukemia. 2010 Feb; 24(2):320-34. View abstract
  126. Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. Blood. 2010 Feb 18; 115(7):1351-3. View abstract
  127. Hypomethylating agents in myelodysplastic syndromes changing the inevitable: the value of azacitidine as maintenance therapy, effects on transfusion and combination with other agents. Leuk Res. 2009 Dec; 33 Suppl 2:S18-21. View abstract
  128. DNA variants in region for noncoding interfering transcript of dihydrofolate reductase gene and outcome in childhood acute lymphoblastic leukemia. Clin Cancer Res. 2009 Nov 15; 15(22):6931-8. View abstract
  129. Atypical presentations of Sweet's syndrome in patients with MDS/AML receiving combinations of hypomethylating agents with histone deacetylase inhibitors. Am J Hematol. 2009 Oct; 84(10):688-9. View abstract
  130. Treating childhood leukemia without cranial irradiation. N Engl J Med. 2009 Sep 24; 361(13):1310; author reply 1311-2. View abstract
  131. A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia. Leukemia. 2009 Dec; 23(12):2259-64. View abstract
  132. Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocol. Blood. 2009 Oct 29; 114(18):3764-8. View abstract
  133. Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis. Pediatr Blood Cancer. 2009 Aug; 53(2):162-7. View abstract
  134. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood. 2009 Sep 24; 114(13):2764-73. View abstract
  135. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood. 2009 Jul 16; 114(3):647-50. View abstract
  136. Gender differences in long-term dexrazoxane cardioprotection in doxorubicin-treated children with acute lymphoblastic leukemia. J Clin Oncol. 2009 May 20; 27(15_suppl):10005. View abstract
  137. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review. Biol Blood Marrow Transplant. 2009 Feb; 15(2):137-72. View abstract
  138. Childhood acute lymphoblastic leukemia: update on prognostic factors. Curr Opin Pediatr. 2009 Feb; 21(1):1-8. View abstract
  139. Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a randomized phase 2 trial by the Cancer and Leukemia Group B (CALGB 19803). Cancer. 2009 Jan 01; 115(1):84-93. View abstract
  140. Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an update. Ecancermedicalscience. 2008; 2:121. View abstract
  141. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell. 2008 Nov 04; 14(5):355-68. View abstract
  142. Acute lymphoblastic leukemia in adolescents and young adults. Curr Hematol Malig Rep. 2008 Jul; 3(3):161-6. View abstract
  143. Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. J Clin Oncol. 2008 Mar 01; 26(7):1106-11. View abstract
  144. Aggressive Langerhans cell histiocytosis following T-ALL: clonally related neoplasms with persistent expression of constitutively active NOTCH1. Am J Hematol. 2008 Feb; 83(2):116-21. View abstract
  145. Alu elements mediate MYB gene tandem duplication in human T-ALL. J Exp Med. 2007 Dec 24; 204(13):3059-66. View abstract
  146. Acute lymphoblastic leukemia in infancy. Pediatr Blood Cancer. 2007 Dec; 49(7 Suppl):1070-3. View abstract
  147. Neuropsychological outcomes from a randomized trial of triple intrathecal chemotherapy compared with 18 Gy cranial radiation as CNS treatment in acute lymphoblastic leukemia: findings from Dana-Farber Cancer Institute ALL Consortium Protocol 95-01. J Clin Oncol. 2007 Nov 01; 25(31):4914-21. View abstract
  148. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet. 2007 Jul 21; 370(9583):240-250. View abstract
  149. Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01. Blood. 2007 Sep 01; 110(5):1607-11. View abstract
  150. Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood. 2007 Aug 15; 110(4):1112-5. View abstract
  151. Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. J Clin Oncol. 2007 Mar 01; 25(7):813-9. View abstract
  152. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood. 2007 Feb 01; 109(3):896-904. View abstract
  153. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006 Aug 20; 24(24):3895-903. View abstract
  154. A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. J Clin Oncol. 2006 Jun 20; 24(18_suppl):6585. View abstract
  155. Phase I study of ON 01910.Na by 3-day continuous infusion (CI) in patients (pts) with advanced cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):13137. View abstract
  156. Outcome of adolescents with acute lymphoblastic leukemia (ALL) treated on Dana-Farber Cancer Institute (DFCI) ALL Consortium Protocols, 1991-2000. J Clin Oncol. 2006 Jun 20; 24(18_suppl):9023. View abstract
  157. Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01. Blood. 2006 Jun 01; 107(11):4508-13. View abstract
  158. Distinctive IGH gene segment usage and minimal residual disease detection in infant acute lymphoblastic leukaemias. Br J Haematol. 2005 Oct; 131(2):185-92. View abstract
  159. Antigen-specific T-cell memory is preserved in children treated for acute lymphoblastic leukemia. Blood. 2005 Sep 01; 106(5):1749-54. View abstract
  160. Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes. J Clin Pharmacol. 2005 May; 45(5):597-602. View abstract
  161. No prognostic effect of additional chromosomal abnormalities in children with acute lymphoblastic leukemia and 11q23 abnormalities. Leukemia. 2005 Apr; 19(4):557-63. View abstract
  162. Failure to define window of time for autologous tumor vaccination in patients with newly diagnosed or relapsed acute lymphoblastic leukemia. Exp Hematol. 2005 Mar; 33(3):286-94. View abstract
  163. Treatment of primary Epstein-Barr virus infection in patients with X-linked lymphoproliferative disease using B-cell-directed therapy. Blood. 2005 Feb 01; 105(3):994-6. View abstract
  164. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004 Oct 08; 306(5694):269-71. View abstract
  165. Diffusion systems for evaluation of biomineralization. Calcif Tissue Int. 2004 Dec; 75(6):494-501. View abstract
  166. Echocardiographic (Echo) monitoring of myocardial injury during doxorubicin (DOX) therapy for childhood acute lymphoblastic leukemia (ALL). J Clin Oncol. 2004 Jul 15; 22(14_suppl):8505. View abstract
  167. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med. 2004 Jul 08; 351(2):145-53. View abstract
  168. Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia. Leuk Res. 2004 Jul; 28(7):679-89. View abstract
  169. Outcomes of a randomized trial of hyperfractionated cranial radiation therapy for treatment of high-risk acute lymphoblastic leukemia: therapeutic efficacy and neurotoxicity. J Clin Oncol. 2004 Jul 01; 22(13):2701-7. View abstract
  170. Secondary cytogenetic aberrations in childhood Philadelphia chromosome positive acute lymphoblastic leukemia are nonrandom and may be associated with outcome. Leukemia. 2004 Apr; 18(4):693-702. View abstract
  171. Utilization of Ig heavy chain variable, diversity, and joining gene segments in children with B-lineage acute lymphoblastic leukemia: implications for the mechanisms of VDJ recombination and for pathogenesis. Blood. 2004 Jun 15; 103(12):4602-9. View abstract
  172. FLT3 mutations in childhood acute lymphoblastic leukemia. Blood. 2004 May 01; 103(9):3544-6. View abstract
  173. Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J Clin Oncol. 2003 Oct 01; 21(19):3616-22. View abstract
  174. Management of an anaphylactoid reaction to methotrexate with a stepwise graded challenge. Pediatr Allergy Immunol. 2003 Oct; 14(5):409-11. View abstract
  175. Sequence analysis of clonal immunoglobulin and T-cell receptor gene rearrangements in children with acute lymphoblastic leukemia at diagnosis and at relapse: implications for pathogenesis and for the clinical utility of PCR-based methods of minimal residual disease detection. Blood. 2003 Dec 15; 102(13):4520-6. View abstract
  176. Height and weight in children treated for acute lymphoblastic leukemia: relationship to CNS treatment. J Clin Oncol. 2003 Aug 01; 21(15):2953-60. View abstract
  177. Newly diagnosed childhood acute lymphoblastic leukemia: update on prognostic factors and treatment. Curr Opin Hematol. 2003 Jul; 10(4):290-6. View abstract
  178. Childhood leukemia: electric and magnetic fields as possible risk factors. Environ Health Perspect. 2003 Jun; 111(7):962-70. View abstract
  179. Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases. Cancer. 2003 Apr 15; 97(8):1920-8. View abstract
  180. Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. Leukemia. 2003 Apr; 17(4):700-6. View abstract
  181. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood. 2003 Aug 01; 102(3):795-801. View abstract
  182. Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. Blood. 2003 Jul 01; 102(1):262-8. View abstract
  183. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell. 2003 Feb; 3(2):173-83. View abstract
  184. Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420. Clin Cancer Res. 2002 Sep; 8(9):2812-9. View abstract
  185. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet. 2002 Jun 01; 359(9321):1909-15. View abstract
  186. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol. 2002 May 15; 20(10):2441-52. View abstract
  187. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002 May 15; 20(10):2429-40. View abstract
  188. Accelerated superfractionated radiotherapy with concomitant boost for locally advanced head-and-neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys. 2002 Mar 15; 52(4):918-28. View abstract
  189. Breast cancer in HIV-positive women: a report of four cases and review of the literature. Cancer Invest. 2002; 20(4):452-7. View abstract
  190. Pediatric Cancer CareLink--supporting home management of childhood leukemia. Proc AMIA Symp. 2002; 290-4. View abstract
  191. Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber ALL Consortium Protocol 87-01. J Clin Oncol. 2002 Jan 01; 20(1):237-46. View abstract
  192. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet. 2002 Jan; 30(1):41-7. View abstract
  193. Excellent therapeutic efficacy and minimal late neurotoxicity in children treated with 18 grays of cranial radiation therapy for high-risk acute lymphoblastic leukemia: a 7-year follow-up study of the Dana-Farber Cancer Institute Consortium Protocol 87-01. Cancer. 2001 Jul 01; 92(1):15-22. View abstract
  194. Bony morbidity in children treated for acute lymphoblastic leukemia. J Clin Oncol. 2001 Jun 15; 19(12):3066-72. View abstract
  195. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001 Mar 01; 97(5):1211-8. View abstract
  196. Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995). Leukemia. 2000 Dec; 14(12):2247-56. View abstract
  197. Cognitive sequelae in children treated for acute lymphoblastic leukemia with dexamethasone or prednisone. J Pediatr Hematol Oncol. 2000 May-Jun; 22(3):206-13. View abstract
  198. Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia. Cancer. 2000 Apr 15; 88(8):1964-9. View abstract
  199. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med. 2000 Apr 06; 342(14):998-1006. View abstract
  200. Induction failure in acute lymphoblastic leukemia of childhood. Cancer. 1999 Mar 15; 85(6):1395-404. View abstract
  201. Incidence of TEL/AML1 fusion in children with relapsed acute lymphoblastic leukemia. Blood. 1998 Dec 15; 92(12):4792-7. View abstract
  202. Intensified therapy for infants with acute lymphoblastic leukemia: results from the Dana-Farber Cancer Institute Consortium. Cancer. 1997 Dec 15; 80(12):2285-95. View abstract
  203. Treatment of childhood leukemia. Curr Opin Oncol. 1997 Jan; 9(1):26-33. View abstract
  204. Cisplatin-based chemotherapy in renal transplant recipients. A case report and a review of the literature. Cancer. 1996 Jan 01; 77(1):160-3. View abstract
  205. Jumping translocations in leukemia. Leukemia. 1995 Apr; 9(4):634-9. View abstract
  206. Members of the src family of nonreceptor tyrosine kinases share a common mechanism for membrane binding. Cell Growth Differ. 1993 Jun; 4(6):475-82. View abstract
  207. Chromosome 21 rearrangement in acute biphenotypic leukemia. Cancer Genet Cytogenet. 1992 Nov; 64(1):56-9. View abstract
  208. del(5q) in acute lymphoblastic leukemia with biphenotypic and early progenitor phenotype. Cancer Genet Cytogenet. 1992 Oct 15; 63(2):89-94. View abstract
  209. Binding of pp60v-src to membranes: evidence for multiple membrane interactions. Biochem Cell Biol. 1992 Oct-Nov; 70(10-11):1187-92. View abstract
  210. Lysine residues form an integral component of a novel NH2-terminal membrane targeting motif for myristylated pp60v-src. J Cell Biol. 1992 Oct; 119(2):415-25. View abstract
  211. Developmental regulation of transmembrane signaling via the T cell antigen receptor/CD3 complex in human T lymphocytes. J Immunol. 1992 Mar 01; 148(5):1315-21. View abstract
  212. Chemotherapy of metastatic Merkel cell cancer. Cancer Invest. 1991; 9(2):129-32. View abstract
  213. Mechanisms of T cell activation by the calcium ionophore ionomycin. J Immunol. 1989 Aug 15; 143(4):1283-9. View abstract
  214. Mechanism of mononuclear cell activation by an anti-CD43 (sialophorin) agonistic antibody. J Immunol. 1989 Jun 15; 142(12):4194-200. View abstract
  215. GANGLIONEUROBLASTOMA. STUDIES OF PATHOLOGIC CHANGES AND CONTENT OF CATECHOLAMINE. Am J Clin Pathol. 1964 Aug; 42:144-51. View abstract
  216. Large adenomatous polyp of Brunner's glands. Am J Clin Pathol. 1961 Nov; 36:438-43. View abstract
  217. A low-resistance valve and indicating flowmeter for respiratory measurements. Science. 1946 Apr 26; 103(2678):537-9. View abstract
  218. A Low-resistance Valve and Indicating Flowmeter for Respiratory Measurements. Science. 1946 Apr 26; 103(2678):537-9. View abstract
  219. A NEW METHOD FOR STUDYING BREATHING, WITH OBSERVATIONS UPON NORMAL AND ABNORMAL SUBJECTS. J Clin Invest. 1944 Nov; 23(6):907-13. View abstract